Shannon Salveson
Nurse Practitioner · Los Angeles, CANPI 1346754694
Payments from drug & device makers
Across 239 payments — averaging $76.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$14K
- United Therapeutics Corporation$1K
- Bayer$1K
- Inari Medical, Inc.$599
- Merck$441
- Johnson & Johnson$357
- plus $34 from 1 others
What the payments were for
- Consulting fees$7,74842%
- Travel & lodging$1,6439%
- Food & beverage$8,92148%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 133 | $14,143 |
| United Therapeutics Corporation | 41 | $1,494 |
| Bayer | 37 | $1,333 |
| Inari Medical, Inc. | 3 | $599 |
| Merck | 14 | $441 |
| Johnson & Johnson(2 entities) | 10 | $357 |
| Liquidia Technologies, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$11,020
- OPSUMIT$6,111
- FLOWTRIEVER CATHETER, S$565
- CT THROMBECTOMY SYSTEM KIT$565
- XARELTO$123
- Adempas$122
How this compares
$18,402 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 14 | $324,979 |
| Tadalafil | 115 | $149,873 |
| AdcircaTadalafil | 22 | $119,391 |
| Sildenafil Citrate | 22 | $13,132 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,300 |
| Potassium Chloride | 58 | $4,234 |
| Furosemide | 73 | $596 |
| Digoxin | 12 | $327 |
| Spironolactone | 18 | $301 |
| Metolazone | 15 | $226 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| United Therapeutics CorporationAdcirca | $1,494 | $119,39122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Los Angeles
- Kristin HorwoodLos Angeles$99K
- Yunying ChenLos Angeles$80K
- Lauren BristowLos Angeles$46K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.